

# Characterization of Patient-Directed Discharge in Patients with Substance Use Disorder(s) Pre- and Post-Implementation of an Inpatient Addiction Consult Service: A Retrospective Cohort Study

Elijah Myers, PharmD, MBA<sup>1</sup>; Lindsay Bowman, PharmD<sup>1</sup>; Suzanne Nesbit, PharmD<sup>1</sup>; Amanda Bertram, MS<sup>2</sup>; Alia Bodnar, MD<sup>2</sup>; Dannielle Brown, PharmD<sup>1</sup>; Megan Buresh, MD<sup>2</sup>; David Wolinsky, MD<sup>3</sup>; Diane Lepley, RN, MSN<sup>4</sup>; Rosalyn Stewart, MD, MBA, MS<sup>2,4</sup>

<sup>1</sup> Department of Pharmacy, Johns Hopkins Hospital; <sup>2</sup> Department of Medicine, Johns Hopkins University School of Medicine; <sup>3</sup> Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; <sup>4</sup> Department of Care Coordination and Resource Management, The Johns Hopkins Hospital

## Introduction

- Emergency department (ED) visits and hospitalizations for patients with substance use disorder (SUD) have increased related comorbidities and SUD-related medical complications.<sup>1</sup>
- Patient-directed discharge (PDD) is associated with increased 30-day hospital readmissions and in-hospital mortality.<sup>2</sup>
- Inpatient addiction consult services (ACS) reduce addiction severity and increase abstinence.<sup>3</sup>
- In July 2020, the Johns Hopkins Hospital introduced a multidisciplinary ACS.
- The impact of this ACS has not been described.

### Objectives

- Compare PDD for patients with a SUD before and after implementation of the ACS.
- Characterize patients with a SUD and PDD before and after implementation of the ACS.
- Describe utilization of the ACS among patients with PDD.
- Delineate treatment strategies initiated prior to PDD for OUD before and after implementation of the ACS.

## Methods

### Study Design, Study Period, Data Collection, and Study Eligibility

- Single-center, retrospective, pre- and post-implementation study
- Pre-implementation: July 1, 2018, to June 30, 2019
- Post-implementation: July 1, 2020, to June 30, 2022
- Patient encounters identified via report generated from the electronic medical record

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> <li>Patients ≥18 years of age</li> <li>At least 1 SUD by ICD-10 diagnosis codes</li> <li>Encounter resulted in PDD</li> </ul>	<ul style="list-style-type: none"> <li>Not having an admission order at time of PDD</li> </ul>

### Primary Outcome

- Comparison of PDD rates pre- and post-implementation of the ACS


### Secondary Outcomes

- Comparison of hospital length of stay (LOS), 30-day readmission rate, baseline demographics, and substance use history
- Description of ACS consult or peer recovery coach (PRC) request processes and completion
- Severity of pain and withdrawal symptoms in an opioid use disorder (OUD) subgroup as well as medication for the treatment of OUD (MOUD) in the first 24 hours

### Statistical Analysis

- Differences in categorical variables between cohorts were analyzed using Chi-square or Fisher's exact test. Continuous variables were compared using Student T-test or Wilcoxon Rank Sum

### Figure 1. Study Eligibility




## Results

**Table 1. Baseline Demographics**

Characteristic	All (n=346)	Pre-Cohort (n=101)	Post-Cohort (n=245)	P value
Age, years (IQR)	41 (33-54)	47 (35-54)	40 (32-54)	0.14
Male, n (%)	228 (65.9)	73 (72.3)	155 (63.3)	0.11
<b>Race, n (%)</b>				<b>0.03</b>
White	170 (49.1)	43 (42.6)	127 (51.8)	
Black/African American	157 (45.4)	54 (53.5)	103 (42.0)	
Other	19 (5.5)	4 (4.0)	15 (6.1)	
PDD in prior 12 months, no. (IQR)	1 (0-2)	1 (0-2)	1 (0-3)	0.54
ED visits in prior 12 months, no. (IQR)	2 (0-7)	3 (1-8)	2 (0-6)	0.21
Co-Occurring SUD, n (%)				0.78
1 SUD	205 (59.2)	61 (60.4)	144 (58.8)	
>1 SUD	141 (40.8)	40 (39.6)	101 (41.2)	
Active tobacco use, n (%)	255 (78.0)	81 (80.2)	174 (77.0)	0.15
Alcohol-related disorder, n (%)	135 (39.0)	36 (35.6)	99 (40.4)	0.41
<b>Opioid-related disorder, n (%)</b>	<b>199 (57.5)</b>	<b>50 (49.5)</b>	<b>149 (60.8)</b>	<b>0.05</b>
Sedative, hypnotic, or anxiolytic-related disorder, n (%)	31 (9.0)	5 (5.0)	26 (10.6)	0.09
<b>Cocaine-related disorder, n (%)</b>	<b>68 (19.7)</b>	<b>12 (11.9)</b>	<b>56 (22.9)</b>	<b>0.02</b>
Other stimulant-related disorder, n (%)	4 (1.2)	1 (1)	3 (1.2)	0.85
Other psychoactive substance-related disorder, n (%)	164 (47.4)	50 (49.5)	114 (46.5)	0.61
Admitting service, n (%)				0.41
Medicine	259 (74.9)	79 (78.2)	180 (73.5)	
Surgery	22 (6.4)	9 (8.9)	13 (5.3)	
Other	65 (18.8)	13 (12.9)	52 (21.2)	
First pain score, score (IQR)	8 (5-10)	8 (5-10)	8 (4-10)	0.66
First COWS score, score (IQR)	5 (2-8)	5 (4-6)	5 (2-8)	0.95
ACS consult ordered, n (%)	---	---	114 (46.5)	---
ACS consult orders completed, n (%)	---	---	68/114 (59.6)	---
PRC referral ordered, n (%)	---	---	54 (22.0)	---
PRC referral orders completed, n (%)	---	---	42/54 (77.8)	---


Data reported as either mean (SD) or median (IQR) for continuous variables; PDD=patient-directed discharge, ED=emergency department, SUD=substance use disorder, COWS=Clinical Opiate Withdrawal Scale, ACS=addiction consult service, PRC=peer recovery coach

**Figure 2. Timeline of PDD with ACS/PRC Involvement**



Data reported as either mean (SD) or median (IQR) for continuous variables

**Figure 3. PDD Rates**



**Table 2. LOS and ED Visits and Readmissions within 30 days**

Outcome	All (n=346)	Pre-Cohort (n=101)	Post-Cohort (n=245)	P value
<b>LOS (hours)</b>	56 (27-102)	53 (22-91)	59 (32-107)	0.12
<b>ED Visits within 30 days</b>	0 (0-2)	0 (0-2)	0 (0-2)	0.95
<b>Readmissions within 30 days</b>	1 (0-2)	1 (0-2)	1 (0-2)	0.63

Data reported as either mean (SD) or median (IQR) for continuous variables

**Table 3. OUD Subgroup**

Outcome	All (n=187)	Pre-Cohort (n=40)	Post-Cohort (n=147)	P value
Active opioid use, n (%)	166 (88.8)	39 (83.0)	127 (90.7)	0.23
<b>Fentanyl use within 24 hours of presentation, n (%)*</b>	<b>121 (70.4)</b>	<b>20 (48.8)</b>	<b>101 (77.1)</b>	<b>0.01</b>
<b>Any MOUD in first 24 hours, n (%)</b>	<b>110 (58.8)</b>	<b>20 (42.6)</b>	<b>90 (64.3)</b>	<b>0.01</b>
Total methadone dose in first 24 hours, mg (IQR)	20 (0-60)	20 (0-50)	20 (0-60)	0.82
Total buprenorphine dose in first 24 hours, mg (IQR)	2 (0-8)	2.5 (0-8)	2 (0-8)	0.75
Any full mu-opioid agonist in first 24 hours, n (%)	95 (50.8)	21 (44.7)	74 (52.9)	0.33
Total MME in first 24 hours, MME (IQR)	7.5 (0-75)	0 (0-45)	7.5 (0-90)	0.21

Data reported as either mean (SD) or median (IQR) for continuous variables; MOUD=medication for opioid use disorder, MME=morphine milligram equivalents; \*some data unavailable

## Conclusion

- Results show low ACS involvement post-implementation encounters
- Potential reasons:
  - Delayed ACS consultation
  - Median time to consult > 24 hours
  - Limited weekend availability of the ACS
- PDD generally happened at the same time as ACS consultation completion
- Need for rapid identification of patients with SUD and earlier ACS consultation, starting in the ED

### Study Definitions

Patient-directed discharge (PDD): patient signing out of the hospital prior to the recommendation of the treating inpatient service  
 Substance use disorders (SUD) of interest: ICD-10 parent codes F10, F11, F13, F14, F15, and F19  
 Medication for opioid use disorder (MOUD): methadone or buprenorphine

### References

- Suen LW, Makam AN, Snyder HR, Reppinger D, Kushel MB, Martin M, Nguyen OK. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018. *J Gen Intern Med.* 2022 Aug;37(10):2420-8. Doi: 10.1007/s11606-021-07069-w
- Tan SY, Feng YJ, Joyce C, Fisher J, Mostahimi A. Association of Hospital Discharge Against Medical Advice With Readmission and In-Hospital Mortality. *JAMA Netw Open.* 2020;3(6):e200609. Doi: 10.1001/jamanetworkopen.2020.6009
- Wakeman SE, Metlay JP, Chang Y, Herman GE, Rigotti NA. Inpatient Addiction Consultation for Hospitalized Patients Increases Post-Discharge Abstinence and Reduces Addiction Severity. *J Gen Intern Med.* 2017 Aug;32(8):909-16. Doi: 10.1007/s11606-017-4077-z

### Disclosures

Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.